Sort
85,873 grants matching “alzheimers”
Commercializing In-Home Supportive Technolgy for Dementia Caregivers
$1,646,582Gene Wang · People Power Company · SB1 · FY2022 · AG
Central Noradrenergic Neuron Subtype Development and Function
$1,646,527Patricia Jensen · National Institute Of Environmental Health Sciences · ZIA · FY2013 · ES
Adult Changes in Thought (ACT) Research Program Core F: Data and Analysis Core
$1,646,262Rod Walker · Kaiser Foundation Research Institute · U19 · FY2022 · AG
Silent Allosteric Modulation of mGluR5 for Safe and Effective Therapy of Alzheimer's Disease
$1,646,216Stephen M Strittmatter · Yale University · U01 · FY2018 · AG
Health and Retirement Study: Harmonized Cognitive Assessment Protocol (HCAP)
$1,645,589Kenneth M Langa · University Of Michigan At Ann Arbor · U01 · FY2021 · AG
Clinical, Imaging, and Pathological Studies in the Oldest Old: The 90+ Study
$1,645,472Claudia H. Kawas · University Of California-Irvine · R01 · FY2016 · AG
CELLULAR COFACTORS, NEURONAL STRESS &RESCUE, AGING &AD
$1,645,328Columbia University Health Sciences · P01 · FY2002 · AG
Alzheimer variants: Propagation of shared functional changes across cellular networks
$1,645,118Philip L De Jager · Columbia University Health Sciences · U01 · FY2023 · AG
EXERCISE TRAIL
$1,644,735Laura D. Baker · University Of California, San Diego · U19 · FY2013 · AG
ALZHEIMERS DISEASE CORE CENTER
$1,644,502New York University School Of Medicine · P30 · FY2003 · AG
RETAIN: A digital therapeutic for Alzheimer's risk reduction
$1,644,444Mark McInnis · Retain Health Inc · R44 · FY2022 · AG
ALZHEIMER DISEASE RESEARCH CENTER
$1,643,678University Of Southern California · P50 · FY2003 · AG
Alzheimer's Disease Research Center
$1,643,177Mount Sinai School Of Medicine Of Nyu · P50 · FY2005 · AG
Human AME study of CT1812, a small molecule in phase 2 clinical trials for the treatment of Alzheimer's disease
$1,642,783Anthony O Caggiano · Cognition Therapeutics, Inc. · SB1 · FY2021 · AG
Multi-scale and multi-modality imaging of neuropathology in VCID
$1,642,682Yulin Ge · New York University School Of Medicine · U24 · FY2025 · NS
Pragmatic Trial of the Effectiveness and Cost-Effectiveness of Dementia Care
$1,642,500David B. Reuben · University Of California Los Angeles · R01 · FY2020 · AG
Epigenomic, transcriptional and cellular dissection of Alzheimer's variants
$1,642,247Manolis Kellis · Massachusetts Institute Of Technology · R01 · FY2018 · AG
Novel Protein Biomarkers of Corticolimbic Pathophysiology in Lewy body Dementia
$1,641,048Nicholas Thomas Seyfried · Emory University · U01 · FY2022 · NS
A global epidemiology of cognitive impairment and dementia due to Alzheimer's disease and related disorders: the COSMIC Collaboration
$1,640,425Perminder S Sachdev · University Of New South Wales · R01 · FY2024 · AG
Higher Order Chromatin and Genetic Risk for Alzheimer's Disease
$1,640,179Panagiotis Roussos · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · AG
Washington University Center for Translational Neuroscience
$1,639,584David M Holtzman · Washington University · P30 · FY2009 · NS
Mechanism Of Action And Functions Of The Gli-related Proteins Glis 1-3
$1,639,389Anton M Jetten · National Institute Of Environmental Health Sciences · ZIA · FY2017 · ES
Indiana Alzheimer Disease Center
$1,639,109Andrew J Saykin · Indiana University Indianapolis · P30 · FY2013 · AG
Clinical & biological signatures of post-traumatic neurodegeneration: Leveraging the TBI Model Systems of Care to accelerate in vivo diagnosis of the late effects of TBI (LETBI)
$1,638,533Kristen Dams-O'Connor · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · NS
Investigating the molecular basis of risk and resilience to Alzheimer's disease
$1,638,330Priyanka Narayan · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2024 · DK